VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Signed informed consent form (ICF)                 │ Signed informed consent form (ICF)                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age 18 to 55 years old (inclusive) as of the date  │ Age 18 to 55 years old (inclusive) as of the date  │     100 │
│ the ICF is signed                                  │ the ICF is signed                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of MS according to the McDonald criteria │ Diagnosis of MS according to the McDonald criteria │     100 │
│ 2010 and cranial MRI scan demonstrating white      │ 2010 and cranial MRI scan demonstrating white      │         │
│ matter lesions attributable to MS within 10 years  │ matter lesions attributable to MS within 10 years  │         │
│ before Screening                                   │ before Screening                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Onset of MS symptoms (as determined by a           │ Onset of MS symptoms (as determined by a           │     100 │
│ neurologist, either at present or retrospectively) │ neurologist, either at present or retrospectively) │         │
│ within 10 years of the date the ICF is signed      │ within 10 years of the date the ICF is signed      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ EDSS score 0.0 to 5.0 (inclusive) at Screening     │ EDSS score 0.0 to 5.0 (inclusive) at Screening     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Completion of all vaccinations required by the     │ Completion of all vaccinations required by the     │     100 │
│ applicable immunization guidelines published by    │ applicable immunization guidelines published by    │         │
│ "ständige Impfkommission" (STIKO)                  │ "ständige Impfkommission" (STIKO)                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of chickenpox or positive test for         │ History of chickenpox or positive test for         │     100 │
│ antibodies against varicella zoster virus (VZV)    │ antibodies against varicella zoster virus (VZV)    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical trial at present │ Participation in another clinical trial at present │     100 │
│ or within 4 weeks of study entry. There may be     │ or within 4 weeks of study entry. There may be     │         │
│ exceptions at the discretion of the Investigator   │ exceptions at the discretion of the Investigator   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has any progressive form of MS                     │ Has any progressive form of MS                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypersensitivity to the active substance, or to    │ Hypersensitivity to the active substance, or to    │     100 │
│ any of the excipients of Lemtrada®                 │ any of the excipients of Lemtrada®                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical, psychiatric, cognitive, or other          │ Medical, psychiatric, cognitive, or other          │     100 │
│ conditions that, in the Investigator's opinion,    │ conditions that, in the Investigator's opinion,    │         │
│ compromise the patient's ability to understand the │ compromise the patient's ability to understand the │         │
│ patient information, to give informed consent, to  │ patient information, to give informed consent, to  │         │
│ comply with the trial protocol, or to complete the │ comply with the trial protocol, or to complete the │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any disability acquired from trauma or another     │ Any disability acquired from trauma or another     │     100 │
│ illness that could interfere with evaluation of    │ illness that could interfere with evaluation of    │         │
│ disability due to MS                               │ disability due to MS                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major systemic disease or other illness that       │ Major systemic disease or other illness that       │     100 │
│ would, in the opinion of the Investigator,         │ would, in the opinion of the Investigator,         │         │
│ compromise patient safety or interfere with the    │ compromise patient safety or interfere with the    │         │
│ interpretation of study results, e.g., current     │ interpretation of study results, e.g., current     │         │
│ peptic ulcer disease or other conditions that may  │ peptic ulcer disease or other conditions that may  │         │
│ predispose to hemorrhage                           │ predispose to hemorrhage                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known bleeding disorder (e.g,. dysfibrinogenemia,  │ Known bleeding disorder (e.g,. dysfibrinogenemia,  │     100 │
│ factor IX deficiency, hemophilia, Von Willebrand's │ factor IX deficiency, hemophilia, Von Willebrand's │         │
│ disease, disseminated intravascular coagulation    │ disease, disseminated intravascular coagulation    │         │
│ (DIC), fibrinogen deficiency, or clotting factor   │ (DIC), fibrinogen deficiency, or clotting factor   │         │
│ deficiency)                                        │ deficiency)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant autoimmune disease including but not   │ Significant autoimmune disease including but not   │     100 │
│ limited to immune cytopenias, rheumatoid           │ limited to immune cytopenias, rheumatoid           │         │
│ arthritis, systemic lupus erythematosus, other     │ arthritis, systemic lupus erythematosus, other     │         │
│ connective tissue disorders, vasculitis,           │ connective tissue disorders, vasculitis,           │         │
│ inflammatory bowel disease, severe psoriasis       │ inflammatory bowel disease, severe psoriasis       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of malignancy, except basal skin cell      │ History of malignancy, except basal skin cell      │     100 │
│ carcinoma                                          │ carcinoma                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major psychiatric disorder that is not adequately  │ Major psychiatric disorder that is not adequately  │     100 │
│ controlled by treatment                            │ controlled by treatment                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Epileptic seizures that are not adequately         │ Epileptic seizures that are not adequately         │     100 │
│ controlled by Treatment                            │ controlled by Treatment                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active infection, e.g., deep-tissue infection,     │ Active infection, e.g., deep-tissue infection,     │     100 │
│ that the Investigator considers sufficiently       │ that the Investigator considers sufficiently       │         │
│ serious to preclude study participation            │ serious to preclude study participation            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In the Investigator's opinion, is at high risk for │ In the Investigator's opinion, is at high risk for │     100 │
│ infection (e.g., indwelling catheter, dysphagia    │ infection (e.g., indwelling catheter, dysphagia    │         │
│ with aspiration, decubitus ulcer, history of prior │ with aspiration, decubitus ulcer, history of prior │         │
│ aspiration pneumonia or recurrent urinary tract    │ aspiration pneumonia or recurrent urinary tract    │         │
│ infection)                                         │ infection)                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Seropositivity for human immunodeficiency virus    │ Seropositivity for human immunodeficiency virus    │     100 │
│ (HIV)                                              │ (HIV)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Infection with hepatitis C Virus                   │ Infection with hepatitis C Virus                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Past or present hepatitis B infection (positive    │ Past or present hepatitis B infection (positive    │     100 │
│ hepatitis B serology)                              │ hepatitis B serology)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active infection with human cytomegaly virus       │ Active infection with human cytomegaly virus       │     100 │
│ (HCMV), Epstein-Barr virus (EBV), varicella-zoster │ (HCMV), Epstein-Barr virus (EBV), varicella-zoster │         │
│ virus (VZV)                                        │ virus (VZV)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Latent tuberculosis unless effective anti-         │ Latent tuberculosis unless effective anti-         │     100 │
│ tuberculosis therapy has been completed, or active │ tuberculosis therapy has been completed, or active │         │
│ tuberculosis                                       │ tuberculosis                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Invasive fungal infections in history and at       │ Invasive fungal infections in history and at       │     100 │
│ present                                            │ present                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cervical cytology other than PAP I or PAP II       │ Cervical cytology other than PAP I or PAP II       │     100 │
│ (Papanicolaou) or cervical high risk human         │ (Papanicolaou) or cervical high risk human         │         │
│ papillomavirus (HPV) positivity                    │ papillomavirus (HPV) positivity                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other illness or infection (latent or active)  │ Any other illness or infection (latent or active)  │     100 │
│ that, in the Investigator's opinion, could be      │ that, in the Investigator's opinion, could be      │         │
│ exacerbated by study medication                    │ exacerbated by study medication                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence (i.e., above the ULN) of anti-thyroid     │ Presence (i.e., above the ULN) of anti-thyroid     │     100 │
│ stimulating hormone receptor antibodies (anti-     │ stimulating hormone receptor antibodies (anti-     │         │
│ TSHR) and anti-thyroid peroxidase antibody (anti-  │ TSHR) and anti-thyroid peroxidase antibody (anti-  │         │
│ TPO)                                               │ TPO)                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Vaccination less than 6 weeks prior to treatment   │ Vaccination less than 6 weeks prior to treatment   │     100 │
│ with Lemtrada                                      │ with Lemtrada                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with antineoplastic or immunosuppressive │ Treatment with antineoplastic or immunosuppressive │     100 │
│ drugs within 8 weeks prior to study inclusion      │ drugs within 8 weeks prior to study inclusion      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intolerance of pulsed corticosteroids, especially  │ Intolerance of pulsed corticosteroids, especially  │     100 │
│ a history of steroid psychosis                     │ a history of steroid psychosis                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to undergo MRI with gadolinium           │ Inability to undergo MRI with gadolinium           │     100 │
│ administration                                     │ administration                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Of childbearing potential with a positive serum    │ Of childbearing potential with a positive serum    │     100 │
│ pregnancy test, pregnant or lactating              │ pregnancy test, pregnant or lactating              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female patients of childbearing potential:         │ Female patients of childbearing potential:         │     100 │
│ Unwilling to agree to use a reliable and           │ Unwilling to agree to use a reliable and           │         │
│ acceptable contraceptive method (Pearl index \<1)  │ acceptable contraceptive method (Pearl index <1)   │         │
│ throughout the study period. These methods         │ throughout the study period. These methods         │         │
│ include: hormone releasing intrauterine device     │ include: hormone releasing intrauterine device     │         │
│ (IUD), hormonal-based contraception, surgical      │ (IUD), hormonal-based contraception, surgical      │         │
│ sterilization, abstinence, or double-barrier       │ sterilization, abstinence, or double-barrier       │         │
│ contraception (condom and occlusive cap            │ contraception (condom and occlusive cap [diaphragm │         │
│ \[diaphragm or cervical cap combined with          │ or cervical cap combined with spermicide])         │         │
│ spermicide\])                                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with (highly) active RRMS disease course  │ Patients with (highly) active RRMS disease course  │      99 │
│ indicated to receive alemtuzumab according to the  │ indicated to receive alemtuzumab according to the  │         │
│ following conditions (at least 1 out of 3          │ following conditions (at least 1 out of 3          │         │
│ conditions has to be fulfilled): 1. ≥2 MS relapses │ conditions has to be fulfilled): 1. =2 MS relapses │         │
│ within 24 months, 2. clinical (≥1 relapse) or MRI  │ within 24 months, 2. clinical (=1 relapse) or MRI  │         │
│ (new gadolinium enhancing lesions) disease         │ (new gadolinium enhancing lesions) disease         │         │
│ activity under therapy with other diseasemodifying │ activity under therapy with other diseasemodifying │         │
│ therapies, 3. severe relapse with high disease     │ therapies, 3. severe relapse with high disease     │         │
│ activity (≥9 T2 hyperintense Lesions and ≥1        │ activity (=9 T2 hyperintense Lesions and =1        │         │
│ gadolinium enhancing lesion) on MRI                │ gadolinium enhancing lesion) on MRI                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Differential blood count \< lower limit of normal  │ Differential blood count < lower limit of normal   │      99 │
│ (LLN) at Screening                                 │ (LLN) at Screening                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Confirmed platelet count \< the LLN of the         │ Confirmed platelet count < the LLN of the          │      99 │
│ evaluating laboratory at Screening or documented   │ evaluating laboratory at Screening or documented   │         │
│ at \<100,000/μL within the past year on a sample   │ at <100,000/µL within the past year on a sample    │         │
│ without platelet clumping                          │ without platelet clumping                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Renal                                              │ Infection with hepatitis C Virus                   │      16 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ SGPT/ALT \>3.0 × ULN                               │ EDSS score 0.0 to 5.0 (inclusive) at Screening     │      18 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ SGOT/AST \>3.0 × ULN                               │ EDSS score 0.0 to 5.0 (inclusive) at Screening     │      21 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin \>1.5 × ULN                              │ Signed informed consent form (ICF)                 │      22 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic                                            │ Infection with hepatitis C Virus                   │      26 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Creatinine \> 1.5 × ULN                            │ Infection with hepatitis C Virus                   │      29 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Has any progressive form of MS                     │      35 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 55 Years                  │ Has any progressive form of MS                     │      35 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alkaline phosphatase \>2.5 × ULN                   │ Has any progressive form of MS                     │      35 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any hepatic or renal function value grade 2 or     │ Medical, psychiatric, cognitive, or other          │      42 │
│ higher at Screening, with the exception of         │ conditions that, in the Investigator's opinion,    │         │
│ hyperbilirubinemia due to Gilbert's syndrome. See  │ compromise the patient's ability to understand the │         │
│ Table below, drawn from the National Cancer        │ patient information, to give informed consent, to  │         │
│ Institute (NCI) Common Terminology Criteria for    │ comply with the trial protocol, or to complete the │         │
│ Adverse Events v4.0 (CTCAE), published 28 May 2009 │ study                                              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 95
Average Levenshtein Ratio of individual lines: 84.91666666666667
OverAll Ratio: 89.95833333333334
